HAS1 Antibody

中文名稱：

HAS1兔多克隆抗體
貨號：

CSB-PA010139LA01HU
規格：

￥440
圖片：
Immunofluorescence staining of A549 cells with CSB-PA010139LA01HU at 1:100, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) HAS1 Polyclonal antibody
Uniprot No.：

Q92839
基因名：

HAS1
別名：

HAS1; HAS; Hyaluronan synthase 1; Hyaluronate synthase 1; Hyaluronic acid synthase 1; HA synthase 1; HuHAS1
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Hyaluronan synthase 1 protein (151-271AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，HAS1 Antibody (CSB-PA010139LA01HU)，的標記方式是Non-conjugated。對于HAS1 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA010139LB01HU	HAS1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA010139LC01HU	HAS1 Antibody, FITC conjugated
Biotin	CSB-PA010139LD01HU	HAS1 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IF

推薦稀釋比：

Application	Recommended Dilution
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Catalyzes the addition of GlcNAc or GlcUA monosaccharides to the nascent hyaluronan polymer. Therefore, it is essential to hyaluronan synthesis a major component of most extracellular matrices that has a structural role in tissues architectures and regulates cell adhesion, migration and differentiation. This is one of the isozymes catalyzing that reaction. Also able to catalyze the synthesis of chito-oligosaccharide depending on the substrate.
基因功能參考文獻：
1. hyaluronic acid synthase-1 promotes malignant transformation via epithelial-to-mesenchymal transition, micronucleation and centrosome abnormalities PMID: 29137675
2. our study indicated a HAS1-miR214-SOX-4 pathway in regulating the growth and metastasis of Esophageal squamous cell carcinoma (ESCC) , providing a promising target for ESCC therapy PMID: 28656277
3. Reduced expression of HAS1 and HAS2 is associated with melanoma progression and suggests that HAS1 and HAS2 have a prognostic significance in cutaneous melanoma. PMID: 27184066
4. The minor allele genotypes of HAS1 SNPs are significantly more frequent in MM, WM, CLL and in affected members of a monoclonal gammopathy-prone family than they are in breast cancer, sporadic MGUS or healthy donors PMID: 24950197
5. transcriptional regulation of the HAS and HAS2-antisense RNA 1 genes, was analyzed. PMID: 25325984
6. HAS1 is the main enzyme responsible for hyaluronan production by normal keratinocytes. PMID: 24658508
7. The HAS1-dependent coat is induced by inflammatory agents and glycemic stress, mediated by altered presentation of either CD44 or hyaluronan, and can offer a rapid cellular response to injury and inflammation. PMID: 24099991
8. Among the genes affected by FAK or HAS3 inhibition were genes, playing role in apoptosis, cell cycle regulation, adhesion, transcription, heatshock and WNT pathways. PMID: 22934709
9. Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma. PMID: 23560496
10. aberrant intronic HAS1 splicing in multiple myeloma patients may rely on intronic HAS1 deletions and mutations that are frequent in MM patients but absent from healthy donors PMID: 23301075
11. TGF-beta1 up-regulation of HAS1 transcription was mediated via Smad3 but not Smad2, while HAS1 induction by IL-1beta was Sp3, not Sp1, dependent. PMID: 23123404
12. Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3 PMID: 23303191
13. HA chains synthesized by HAS1 and HAS2 contribute to outflow resistance, while hyaluronan produced by HAS3 does not appear to play a significant role. PMID: 22695958
14. analysis of changes in cervical glycosaminoglycan composition during normal pregnancy and preterm birth: Has1 is expressed in preterm birth, while Has2 is induced at term PMID: 22529214
15. this study provides strong evidence that HAS1-driven Hyaluonan-synthesis is a target of estradiol in human vascular smooth muscle cells PMID: 21901291
16. HYAL-1 and HAS1 expression predicted bladder cancer metastasis, and HYAL-1 expression also predicted disease-specific survival. PMID: 20960509
17. Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma PMID: 20875124
18. Data show that a significant in expression levels of HA synthases (HASs) and hyaluronidases (Hyals) was observed in vitro on stimulation of epithelial ovarian carcinoma cells by gonadotropins. PMID: 20072653
19. hyaluronan synthase expression in prostate adenocarcinoma cells PMID: 11790779
20. characterization of expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients PMID: 12239172
21. Expression of HAS1 in Waldenstrom's macroglobulinemia. Variants of HAS1 synthesize the intracellular HA ligand for RHAMM and may contribute to genetic instability in Waldenstrom's macroglobulinemia. PMID: 12720129
22. Expression of each hyaluronan synthase isoform is regulated differently by growth factors and cytokines in vascular endothelial cells. Expressed in proliferative membranes from proliferative vitreoretinal diseases. May affect progression of diseases. PMID: 14636845
23. hyaluronan synthase 1 variants have a role in progression of multiple myeloma PMID: 15731173
24. Increased HAS1 expression and an increase in serum hyaluronan in endometrial cancer may be associated with disease progression through myometrial invasion and lymph-vascular space involvement PMID: 15870928
25. IkappaB kinase and IkappaBalpha reveal NF-kappaB-dependent as well as NF-kappaB-independent pathways of HAS1 activation PMID: 16258173
26. mRNA for HAS1 is undetectable but HAS3 mRNA can be readily detected in freshly isolated CD133+ as well as in CD133- umbilical cord blood (UCB) cells. mRNA for HAS2 can only be detected in CD133+ progenitor cells. PMID: 16564133
27. Evidence is provided that in type-B synoviocytes (TBS) HAS1 is a gene that depends on the transcription factor nuclear factor kappa B (NF-kappaB) for its activation. PMID: 16723203
28. The aim of this study was to evaluate how TNF-alpha, IFN-gamma,IL-1beta, and exposition to oxidative stress may modulate HAS activities in normal human skin fibroblasts. PMID: 16786194
29. Interleukin-1beta stimulation resulted in induction of HAS1 and HAS2 transcription but did not induce phenotypic differentiation or induce hyaluronan coat assembly PMID: 17611197
30. HAS1 captured in this pull-down approach is readily immunodetected by Western blot analysis using appropriate antibodies. PMID: 17904513
31. Treatment of fibroblasts with growth factors up-regulated HAS gene expression and increased HAS enzymes and HA production. PMID: 17922656
32. HAS1 regulates bladder cancer growth and progression by modulating hyaluronic acid synthesis and hyaluronic acid receptor levels. PMID: 18199543
33. HAS1 is activated by Epstein-Barr virus and synthetic double- and single-stranded viral RNA analogs PMID: 18400745
34. genetic contributions toward aberrant splicing of the HAS1 gene in multiple myeloma and Waldenstrom macroglobulinemia were characterized; 3616 bp in HAS1 exons and introns involved in aberrant splicing, from 17 patients were sequenced PMID: 18815290
35. HAS expression in human articular chondrocytes during the de- and re-differentiation processes. PMID: 19148550
36. By intensive sequencing of the hyaluronan synthase 1 (HAS1) gene in malignant and normal cells from patients with WM, we have identified both types of mutation in HAS1 exons and introns. PMID: 19362966
37. HAS1, HAS2 and HAS3 expression is not consistently elevated in ovarian carcinomas. PMID: 19435493
38. HAS1 (Hyaluronan Synthase 1) splice variants multimerize with and modulate normally spliced HAS1 protein PMID: 19451652
39. Transfection with siHAS2 and siHAS1 showed that mainly HAS1 synthesized high molecular weight HA regulates HT1080 cell motility. PMID: 19577615
40. HAS activity can be modulated by post-translational modification, such as phosphorylation and N-glycosylation PMID: 19737932
顯示更多

收起更多
亞細胞定位：

Membrane; Multi-pass membrane protein.
蛋白家族：

NodC/HAS family
組織特異性：

Widely expressed. Highly expressed in ovary followed by spleen, thymus, prostate, testes and large intestine. Weakly expressed in small intestine.
數據庫鏈接：

HGNC: 4818

OMIM: 601463

KEGG: hsa:3036

STRING: 9606.ENSP00000222115

UniGene: Hs.57697

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human